Kara Johnson
Immunology and Microbiology · The Ohio State University
Publications
102
Citations
3,204
Est. group size
~1
Recurring co-author estimate
Active years
40
Publishing since 1987
Kara Johnson's work focuses on blood cancers, particularly acute myeloid leukemia (AML) and clonal T-cell diseases, including how leukemia cells develop drug resistance and how patient-specific immune-based therapies might target these diseases. The research combines laboratory studies of cancer cell biology with translational approaches aimed at guiding treatment decisions for patients.
Publication output was minimal before 2022 but rose sharply in 2023, followed by a decline through 2024-2026, suggesting a burst of concentrated output rather than steady long-term growth.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- DDX41-Mutated AML: A Case Report and Perspectives
JCO Precision Oncology · 2026
- A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia
Blood · 2025
- Supplementary Methods S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2025
- Supplementary Figure S4 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2025
- Supplementary Figure S2 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2025
- Supplementary Figure S5 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2025
- Supplementary Figure S3 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2025
- Supplementary Table S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2025
- Supplementary Figure S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2025
- Kratom‐Associated Diffuse Alveolar Haemorrhage: A Clinical Image
Respirology Case Reports · 2025
- Abstract 2548: Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an <i>ex vivo</i> drug sensitivity assay using cryopreserved primary samples
Cancer Research · 2024
- Supplementary Table S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2024
- Supplementary Figure S5 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2024
- Supplementary Figure S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2024
- Supplementary Methods S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
2024
- Blood×6
- Journal of the American Society of Nephrology×2
- Nature×1
- Cancer Cell×1
- Advances in Nutrition×1
- Julika Kaplan
Immunology and Microbiology · Indiana University
- Amanda R. Panfil
Immunology and Microbiology · The Ohio State University
- David J. Waters
Immunology and Microbiology · Purdue University West Lafayette
- Jacob Al-Saleem
Immunology and Microbiology · The Ohio State University
- Patrick Green
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile